The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
| العنوان: | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease |
|---|---|
| المؤلفون: | Patrizia Mecocci, Nicholas J. Ashton, Kaj Blennow, Dag Aarsland, Bruno Vellas, Oskar Hansson, Pedro Rosa-Neto, Eric Westman, Joel Simrén, Henrik Zetterberg, Hilkka Soininen, Michael Schöll, Thomas K. Karikari, Iwona Kłoszewska, Juan Lantero-Rodriguez, Niklas Mattsson-Carlgren, Antoine Leuzy, Simon Lovestone, Magda Tsolaki, Andrea Lessa Benedet, Abdul Hye |
| المصدر: | Alzheimer's & Dementia |
| بيانات النشر: | John Wiley and Sons Inc., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Epidemiology, Disease, phosphorylated tau, 0302 clinical medicine, Cognitive decline, Gray Matter, Phosphorylation, medicine.diagnostic_test, Glial fibrillary acidic protein, biology, Health Policy, Area under the curve, Brain, Alzheimer's disease, Prognosis, Magnetic Resonance Imaging, Psychiatry and Mental health, Female, medicine.medical_specialty, Neurofilament light, tau Proteins, Plasma biomarkers, 03 medical and health sciences, Cellular and Molecular Neuroscience, Developmental Neuroscience, Alzheimer Disease, Internal medicine, mental disorders, medicine, Dementia, Humans, Cognitive Dysfunction, Aged, Amyloid beta-Peptides, business.industry, Featured Articles, Magnetic resonance imaging, Featured Article, medicine.disease, 030104 developmental biology, plasma biomarkers, biology.protein, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery, Biomarkers |
| الوصف: | Introduction This study investigated the diagnostic and disease‐monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results Phosphorylated‐tau181 (P‐tau181), neurofilament light, amyloid‐β (Aβ42/40), Total‐tau and Glial fibrillary acidic protein were altered in AD dementia but P‐tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P‐tau181 was increased in MCI converters compared to non‐converters. Higher P‐tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P‐tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. Discussion P‐tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P‐tau181 as a non‐invasive and cost‐effective diagnostic and prognostic biomarker in AD. |
| اللغة: | English |
| تدمد: | 1552-5279 1552-5260 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d419a932d7cd760a308bfd24693e84Test http://europepmc.org/articles/PMC8359457Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....73d419a932d7cd760a308bfd24693e84 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15525279 15525260 |
|---|